Welcome to our dedicated page for Rezolute SEC filings (Ticker: RZLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rezolute, Inc. filings document regulatory disclosures for a Nasdaq-listed Nevada biopharmaceutical company developing ersodetug for hyperinsulinism. Recent Current Reports on Form 8-K include Regulation FD disclosures on the sunRIZE congenital hyperinsulinism program, FDA meeting updates, investor presentations, expanded access data in tumor hyperinsulinism, and exhibits containing related press releases and corporate materials.
The filing record also includes Form 8-K disclosures for quarterly financial results, annual stockholder voting matters, board elections and amendments to executive employment agreements. These documents record the company’s clinical-development communications, governance actions, capital-market disclosures and material corporate agreements.
The Vanguard Group amended its Schedule 13G reporting for Rezolute Inc., stating it beneficially owns 0 shares of common stock, representing 0% of the class as disclosed in the filing. The amendment explains an internal realignment and separate reporting by subsidiaries effective January 12, 2026.
Rezolute announced outcomes from a recent Type B meeting with the FDA about sunRIZE, its Phase 3 trial of ersodetug for congenital hyperinsulinism. The study previously reduced hypoglycemia events but failed its primary endpoint because the benefit versus placebo was not statistically significant. FDA acknowledged challenges with behavior-driven and self-monitored glucose measures in this rare disease and reviewed continuous glucose monitoring data and open-label extension trends suggesting improved glycemic control and reduced background therapies. FDA encouraged Rezolute to submit full study reports and analysis datasets so the agency can independently determine whether evidence could support a marketing application or if more data are needed. Rezolute expects to provide a program update in the second half of 2026.
Rezolute, Inc.’s Chief Medical Officer Brian Kenneth Roberts reported a mandatory share disposition tied to equity compensation. On the RSU vesting date, he disposed of 11,439 common shares to cover tax withholding obligations at a weighted average price of $2.99 per share, with individual sale prices ranging from $2.98 to $3.07. After this tax-withholding transaction, he directly holds 296,913 common shares and indirectly holds 15,500 common shares in an IRA.
Rezolute, Inc. CFO Daron Evans reported a mandated tax-withholding share disposition related to restricted stock units. On this Form 4, he disposed of 11,438 common shares at a weighted average price of $2.99 per share to cover tax obligations from RSU vesting, as required by the company’s sell-to-cover election and not as a discretionary trade. Following the transaction, he directly holds 404,462 common shares. He also reports additional indirect holdings in Rezolute shares held by his spouse, minor children, and PoC Capital LLC, a California limited liability company he manages, with beneficial ownership in the LLC disclaimed except to the extent of his pecuniary interest.
Rezolute, Inc. CEO and director Nevan C. Elam reported a tax-related share disposition. On March 2, 2026, 27,618 common shares were disposed of at a weighted average price of $2.99 per share to cover tax withholding obligations from vested RSUs.
The company required this "sell to cover" transaction, so it was not a discretionary sale by Elam. After the transaction, Elam directly held 613,501 Rezolute common shares.
Invus Public Equities and related investment entities report that they no longer beneficially own any shares of Rezolute, Inc. common stock, representing 0% of the class as of December 31, 2025. Each reporting person lists 0 shares for voting and dispositive power, confirming ownership has fallen below the 5% reporting threshold. The filing formally amends prior Schedule 13G disclosures and includes a certification that the securities were not acquired or held for the purpose of changing or influencing control of Rezolute.
Rezolute, Inc. reported a larger net loss as it advances late-stage programs for hyperinsulinism. For the six months ended December 31, 2025, net loss was $40.9 million, with $27.5 million in research and development and $16.5 million in general and administrative expenses.
In December 2025, its Phase 3 sunRIZE trial in congenital hyperinsulinism failed to meet its primary and key secondary endpoints, prompting a workforce reduction of 29 employees and $1.5 million in one-time severance costs. Management still sees pharmacologic activity for ersodetug and plans an FDA meeting by the end of Q1 2026 to discuss a potential path forward.
The Phase 3 upLIFT trial in tumor hyperinsulinism is ongoing as a single-arm registrational study, with topline data expected in the second half of 2026. As of December 31, 2025, Rezolute held $11.9 million in cash and cash equivalents and $121.0 million in marketable debt securities, and believes this is sufficient to fund operations for at least 12 months.
Rezolute, Inc. reported a larger net loss for its fiscal second quarter ended December 31, 2025, as it increased spending on its late-stage rare disease programs. Net loss was $22.8 million, compared with $15.7 million a year earlier, while basic and diluted net loss per share remained $(0.22) on a higher share count.
Research and development expenses rose to $14.3 million from $12.6 million, mainly from higher clinical trial and employee-related costs, including severance tied to a December 2025 reduction in force. General and administrative expenses more than doubled to $9.9 million from $4.5 million, driven by higher professional fees and additional severance.
Cash, cash equivalents and investments in marketable securities totaled $132.9 million as of December 31, 2025, down from $167.9 million as of June 30, 2025, reflecting continued funding of operations. Rezolute highlighted ersodetug, its fully human monoclonal antibody designed to treat hypoglycemia from all forms of hyperinsulinism, as its lead program in both congenital and tumor-related HI.
Bank of America Corporation filed a Schedule 13G reporting beneficial ownership of 6,064,486 shares of Rezolute, Inc. common stock, representing 6.5% of the class. The percentage is based on 92,727,532 shares outstanding reported by Rezolute in a recent Form 10‑Q.
Bank of America reports no sole voting or dispositive power over Rezolute shares and shared voting and dispositive power over all 6,064,486 shares. The filing is made on behalf of Bank of America and wholly owned subsidiaries BofA Securities, Inc., Bank of America, N.A., and Merrill Lynch International.
The shares are certified as acquired and held in the ordinary course of business, and not for the purpose of changing or influencing control of Rezolute.
The Vanguard Group reported beneficial ownership of 4,788,511 shares of Rezolute Inc. common stock, representing 5.16% of the class as of December 31, 2025.
Vanguard reports no sole voting or dispositive power, with shared voting power over 592,109 shares and shared dispositive power over all 4,788,511 shares, largely on behalf of its clients. The firm states the position is held in the ordinary course of business and not to change or influence control of Rezolute.
Vanguard also notes an internal realignment effective January 12, 2026, after which certain subsidiaries or business divisions that pursue the same strategies are expected to report beneficial ownership separately on a disaggregated basis.